title: PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
abstract: Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is common in breast cancer. PI3K pathway activation has been associated with tumor growth and progression, and thus is a promising target for breast cancer therapy. Agents targeting the PI3K pathway can restore sensitivity to standard breast cancer therapies, including endocrine, HER2-targeted agents and chemotherapy, by suppressing PI3K pathway activation, which is central to the development of therapeutic resistance. The combination of endocrine therapy and PI3K pathway (mTOR) inhibition has proven clinical benefit, and novel combination strategies involving PI3K pathway inhibitors and other investigational targeted therapies are now being explored clinically in patients with breast cancer.
authors.affiliation: Cleveland Clinic, Taussig Cancer Institute, 9500 Euclid Ave, R-35, Cleveland, OH 44195, USA.
authors.forename: Jame
authors.initials: J
authors.lastname: Abraham
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases
keywords: AKT inhibitor; PI3K inhibitor; breast cancer; combination therapy; mTOR inhibitor